内容摘要：

The main objective of nanomedicine research is the development of nanoparticles as drug delivery systems or drugs per se to tackle diseases, such as cancers, which are a leading cause of death within developed nations. Nanotechnology, in particular the nanocarrier approach for drug delivery, has attracted much attention in the development of targeted anticancer therapies aimed to avoid, for instance, the systemic toxicities of classical cytotoxic drugs. The nanotherapeutic technologies currently used and proposed for anticancer drug delivery therapies are as follows: polymer-drug conjugates, polymer micelles, liposomes, dendrons, dendrimers, mesoporous silica, albumin nanoparticles, metallic nanoparticles, chitosan nanoparticles etc. Results from pre-clinical and clinical trials using nanoparticles are encouraging, suggesting that nanoparticles provide strong opportunities to design and tune up particular properties of drugs (nanocarrier approach), and to develop nanodevices as drugs per se. Such interventions are not possible with other types of therapeutics and have thus fueled much enthusiasm with regards the wealth of opportunities afforded by this emerging field of nanoscience in oncology.

主讲人简介：

Serge Mignani obtained a “diplôme d’ingénieur” degree in 1977 fromthe ‘Ecole Nationale Supéreure de Chimie de Rennes’ (University of Rennes,France). In 1978, he joined the Catholic University of Louvain-la-Neuve(Belgium) for a Ph.D. training under the supervision of Prof H. G. Viehe. Heobtained his Ph.D. degree in 1981. In 1985‐86, he joined theUniversity of Madison (USA) for a postdoctoral stay under the supervision ofProf B. M.Trost (palladium‐catalyzed carboxylativetrimethylenemethane cycloadditions). In 1981, he joined Rhône-Poulenc(currently Sanofi) at the Vitry Research Center, where he was Head of theMedicinal Chemistry Department and Scientific Director. In 1995, he joined CNRSas an adjunct professor. His research interests included medicinal chemistry,organic synthesis, nanotechnologies, drug delivery and vectorisationapproaches. His research team has been involved successively in the preparationof new anti‐convulsive, anxiolytic,anti‐depressive, anti‐ischaemic, anti‐HIV, anti‐diabetic, anti‐bacterial and anti‐tumor agents with original mechanism of action. Morethan ten clinical candidates have been disclosed by his team. Serge Mignani isauthor of more 120 publications and more 100 patents. More than 70 invitedplenary lectures and conferences have been presented.

讲座语言：英语